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Non-standard Abbreviations and Acronyms 
Acetylated tripeptide proline-glycine-proline (ac-PGP); artery tertiary lymphoid organs (ATLOs); 
giant cell arteritis (GCA); extracellular matrix (ECM); high endothelial venules (HEVs); matrix 
metalloproteinases (MMPs); NOD SCID Gamma (NSG); peripheral blood mononuclear cells 
(PBMC); tissue inhibitors of metalloproteinases (TIMPs); vascular smooth muscle cells (VSMCs). 
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Giant cell arteritis (GCA) is a chronic inflammatory vasculopathy of the medium and large sized 
arteries including the external carotid branches, the ophthalmic, vertebral, subclavian, and axillary 
arteries, as well as thoracic aorta1. Severe granulomatous vasculitis, with profound T cell and 
macrophage infiltration and activation into the otherwise immunoprivileged vascular wall, results in 
occlusion of vascular  lumen leading to ischemic symptoms, such as loss of vision in ca. 15% of 
patients1. Dissection and aneurysm formation, especially in the aorta also occur. While very long-term 
high dose glucocorticosteroid treatments are used in controlling the inflammation to alleviate 
symptoms, they are associated with complications and when glucocorticoids are gradually reduced, 
disease flares occur frequently1. Thus, glucocorticoid sparing regimens including methotrexate as well 
as biologics such as tociluzimab or abatacept have been tested to further reduce risk of relapse and 
lower serious systemic side effects2. A need for additional potentially safer therapies is very evident. 
While our understanding of immunopathology of advanced disease has significantly improved over 
the years, researchers know less about the early stages of the disease enabling the breakdown of 
immunoprivilege. As with many vascular disorders linked to vascular remodeling, a possible focus 
lies in matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), as final effectors of 
pathological vascular remodeling and neovascularization. Accumulating evidence suggest that MMPs 
can also regulate vascular inflammation3, making them a particularly interesting therapeutic target in 
vasculitis. Indeed, in GCA high gelatinase expression and activity occurs at the granulomatous areas 
surrounding the internal elastic lamina4. 
In the present issue of Circulation Research, the Weyand group present a pathogenetic role of 
monocyte and macrophage derived MMP-9 in facilitating T cell infiltration into the vessel wall5. In a 
series of elegant in vitro mechanistic experiments, using an artificial collagen I and IV basement 
membrane model, they show that GCA patient monocytes show an increased ability to pass through 
the collagen barrier, but even more importantly, enable rapid T cell invasion into the matrix, that 
without monocytes did not occur5. The ability to penetrate through the collagen layers was dependent 
on MMP-9 release from GCA monocytes. To verify the potential translational value of their finding, 
as in a number of their previous publications, the authors have used a humanized chimera model 
created by grafting human temporal or axillary arteries subcutaneously into the back of 
immunocompromised NOD SCID Gamma (NSG) mice. Adoptive transfer of peripheral blood 
mononuclear cells (PBMC) from a GCA patient into the chimeras induces vasculitis6. Despite not 
being ideal for all purposes, this model addresses key questions linked to human vascular 
immunobiology. In this model, systemic blockade of MMP-9 prevented several vasculogenic 
mechanisms, reducing T cell invasion into the vessel and inhibiting neovascularization and intimal 
hyperplasia. At the same time, administration of recombinant MMP-9 led to increased vascular 
inflammation. These effects of MMP-9 were dependent on destruction of the basement membrane, 
induction of neoangiogenesis and vascular remodeling mediated by PDGF and FGF and also, at least 
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in part, through pro-inflammatory effects induced by the products of extracellular matrix (ECM) 
degradation (matrikines), such as the acetylated tripeptide proline-glycine-proline (ac-PGP). 
Researchers have known for some time that there is increased expression of gelatinases MMP-2 and 
MMP-9 in human GCA specimens in macrophages, smooth muscle cells (VSMCs) and fibroblasts7. 
However, this study sheds a new light on the potential contribution of MMPs to the early-onset of the 
pathology. Interestingly, in the present study MMP-9 expression was found predominantly in 
monocytes and macrophages. One may postulate that at an early stage of disease, preceding T cell 
invasion, this source predominates while at later stages of vascular destruction and remodeling other 
cell types may contribute as well. Moreover, while authors have focused on MMP-9, as the MMP 
which is most abundant in monocytes and macrophages, a very a significant overexpression of MMP-
2 and MMP-7 was also observed in GCA. Future studies need to take this into account when trying to 
think about future strategies of metalloproteinase inhibition in vasculitis. While providing important 
clues regarding the role of MMP-9 producing monocytes as critical checkpoints in the pathogenesis of 
vasculitis and associated leukocyte intramural infiltration, the translational diagnostic, prognostic 
and/or therapeutic usefulness of these new findings has yet to be provided. 
It is however important to point out that production of MMP-9 and MMP-2 by macrophages as well 
as ‘synthetic’ VSMCs is increased in a number of other chronic vascular inflammatory diseases apart 
from vasculitis. Aortic abdominal aneurysms, atherosclerotic plaque rupture leading to myocardial 
infarction and stroke or hypertension are prime examples. In all of these pathologies vascular and 
perivascular inflammation is a prominent pathognomonic feature8. Therefore, the data from Watanabe 
et al.5 could in principle shed light on key early mechanism(s) regulating immune cell trafficking in 
other forms of vascular8 or cardiac9 inflammation. 
A number of important questions arise from this work. For example, in the advanced stages of 
experimental atherosclerosis, researchers have shown that T cells can extravasate in the aortic 
adventitia mainly via high endothelial venules (HEVs), to form structured artery tertiary lymphoid 
organs (ATLOs) able to control vascular immune responses in situ10. Is MMP-9 produced by 
monocytes and macrophages pivotal in this process? In other words, is MMP-9 able to facilitate T cell 
infiltration through high endothelial venules or are other pathways involved in this process but not 
addressed by Watanabe and colleagues? Gelatinases are in fact known to cleave many different 
targets, for example chemokines and cytokine receptors, which in turn may regulate cell migration, 
invasion and in result critically affect the development of vascular inflammation11. It would be also 
important to assess the net contribution of MMP-9 to intramural infiltration of other immune cell 
subsets. 
Whatever the exact mechanism is, the study raises the possibility of therapeutic targeting of MMP-9 
in the control of vascular inflammation. However, our enthusiasm may be somewhat dampened by the 
fact that various modalities of MMP targeting have failed in clinical trials to date, including 
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cardiovascular risk outcome trials in human aortic aneurysms12 or atherosclerotic disease13. One 
interpretation could be that MMP-inhibitors were tested in advanced stages of disease, while it might 
be more efficient to inhibit gelatinases at early stages of vascular inflammation. This prospect is 
interesting in the light of novel therapeutic approaches available to relatively safely target MMPs such 
as the inhibitor of elastolytic matrix metalloproteinases XL78414. Moreover specific MMP-9 inhibitor 
Andecaliximab/GS-5745 has entered phase 2/3 clinical trials showing good tolerability although low 
clinical efficacy in Crohn’s disease or ulcerative colitis15. While we are unquestionably still far from 
successful translation, metalloproteinases seem to still have quite a lot to teach us about initiation and 
propagation of vascular inflammation. 
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Figure 1: MMP-9 role in Giant Cell Arteritis. MMP-9-producing monocytes/macrophages (1) 
degrade the extracellular matrix enabling T cells homing into the vascular wall (2). MMP-9 and 
collagen IV breakdown products such as matrikines (3) stimulate immune cells to produce pro-
inflammatory cytokines (IL-1β, IL-6, IL-21, IFN-γ) (4) leading to a further increase in intramural 
infiltration of leukocytes and their activation (5). In addition, MMP-9 promotes vascular angiogenesis 
(6) and intimal hyperplasia by inducing release of growth factors (7). 
